Exelixis (EXEL) closed at $69.57 on November 6, 2026, up 1.3% from the previous close, on volume of 1,827,547 shares (30-day average 2,461,324).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 3, 2026 | Call Spread | 20-Nov-2670 : 75 C | 2,968 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Leerink Partners Sticks to Its Hold Rating for Exelixis (EXEL)
TipRanks (Thu, 5-Nov 9:31 AM ET)
Exelixis Lines Up Four November Investor-Conference Fireside Chats With 30-Day Webcast Replays
Market Chameleon (Wed, 4-Nov 4:06 AM ET)
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
Business Wire (Tue, 3-Nov 4:05 PM ET)
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Business Wire (Thu, 29-Oct 4:05 PM ET)
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Business Wire (Thu, 15-Oct 4:05 PM ET)
Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm
PRNewswire (Mon, 12-Oct 8:35 PM ET)
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
Business Wire (Tue, 1-Sep 4:05 PM ET)
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
Business Wire (Mon, 31-Aug 2:30 PM ET)
Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky
PRNewswire (Mon, 17-Aug 10:09 AM ET)
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
Business Wire (Sun, 16-Aug 6:24 PM ET)
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Exelixis trades on the NASDAQ stock market under the symbol EXEL.
As of November 6, 2026, EXEL stock price climbed to $69.57 with 1,827,547 million shares trading.
EXEL has a beta of 0.26, meaning it tends to be less sensitive to market movements. EXEL has a correlation of 0.01 to the broad based SPY ETF.
EXEL has a market cap of $16.98 billion. This is considered a Large Cap stock.
Last quarter Exelixis reported $659 million in Revenue and $.94 earnings per share. This beat revenue expectation by $9 million and exceeded earnings estimates by $.06.
In the last 3 years, EXEL traded as high as $73.69 and as low as $19.20.
The top ETF exchange traded funds that EXEL belongs to (by Net Assets): IJH, VTI, VB, XMHQ, XBI.
EXEL has outperformed the market in the last year with a price return of +70.5% while the SPY ETF gained +10.8%. EXEL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +33.3% and +7.8%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
EXEL support price is $67.17 and resistance is $70.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EXEL shares will trade within this expected range on the day.
